Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.37 |
| ▸ | THRA | P10827 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | ASIC1 | P78348 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749428 | 1.00 | NPBWR1 (0.37) | NPBWR1THRATHRBASIC1MCHR1 | |
| SCHEMBL21769494 | 0.90 | NPBWR1 (0.35) | NPBWR1THRATHRBASIC1MCHR1 | |
| SCHEMBL21749466 | 0.85 | NPBWR1 (0.38) | NPBWR1THRATHRBMCHR1CYP2C9 | |
| SCHEMBL21749362 | 0.84 | THRB (0.45) | THRATHRB | |
| SCHEMBL21749363 | 0.84 | THRB (0.45) | THRATHRB | |
| SCHEMBL28566985 | 0.80 | NPBWR1 (0.43) | NPBWR1THRATHRBMCHR1CYP3A4 | |
| SCHEMBL21749429 | 0.80 | NPBWR1 (0.36) | NPBWR1THRATHRB | |
| SCHEMBL21749369 | 0.80 | THRA (0.38) | NPBWR1THRATHRB | |
| SCHEMBL21749380 | 0.79 | NPBWR1 (0.47) | NPBWR1THRATHRBMCHR1 | |
| SCHEMBL21769493 | 0.77 | NPBWR1 (0.36) | NPBWR1THRATHRBMCHR1SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | NPBWR1 158/4885THRA 2/4885THRB 1/4885 |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | NPBWR1 158/4885THRA 2/4885THRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.